Buspirone transdermal - Acrux

Drug Profile

Buspirone transdermal - Acrux

Alternative Names: Buspirone MDTS®

Latest Information Update: 14 Jun 2007

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Acrux
  • Class Antidepressants; Anxiolytics; Pyrimidines; Small molecules; Spiro compounds
  • Mechanism of Action Serotonin 1A receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Anxiety disorders; Fibromyalgia

Most Recent Events

  • 22 Aug 2005 Phase I trials have been completed for Anxiety disorders and Fibromyalgia; further development will continue once a partnership agreement has been secured
  • 07 Mar 2005 Phase-I clinical trials in Fibromyalgia in Australia (Transdermal)
  • 02 Jul 2004 Buspirone transdermal is available for licensing (http://www.acrux.com.au)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top